GEN Roundup: Kinase Assays from Preliminary Screens to “Smart” Deployment
GEN Interviewed Six Experts to Explore Kinase Assays
When the Pressure Is High the Dementia Is Low
Sounds of Science Podcast
Tuning Up or Taming Immune Responses
New Immunotherapeutic Strategies Include Bispecific Antibodies, Engineered Adenoviruses, and Specifically Formulated Vaccines against Cancer
The Promise of Tumor Mutational Burden for Cancer Immunotherapy
Quantitative Biomarkers Could Be the Next Step for Precision Oncology
For full access to this article login to GEN Select now.
Repligen Now a Bioprocess Product Firm
One-Time Therapeutics Player Bets Future on Working as Supplier to Bioprocess Companies
- Repligen, once a strongly focused therapeutics firm, has transformed itself into a bioprocess products company in only a few years’ time. As the company’s former COO Tony J. Hunt takes the helm as president and CEO after the May retirement of Walter C. Herlihy, Ph.D., that transformation will continue ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.